Search results for TNF-alpha

Brilliant Violet 421 anti-mouse TNF-alpha Antibody anti-TNF-alpha - MP6-XT22, BioLegend, 506328

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivityin vivoandin vitro(Cat. No. 506310). Forin vivostudies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9in vivodetection5, immunofluorescence, and immunocytochemistry.Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Alexa Fluor 700 anti-mouse TNF-alpha Antibody anti-TNF-alpha - MP6-XT22, BioLegend, 506338

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivityin vivoandin vitro(Cat. No. 506310). Forin vivostudies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9in vivodetection5, immunofluorescence, and immunocytochemistry.Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Alexa Fluor 647 anti-mouse TNF-alpha Antibody anti-TNF-alpha - MP6-XT22, BioLegend, 506314

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivityin vivoandin vitro(Cat. No. 506310). Forin vivostudies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9in vivodetection5, immunofluorescence, and immunocytochemistry.Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Brilliant Violet 650 anti-mouse TNF-alpha Antibody anti-TNF-alpha - MP6-XT22, BioLegend, 506333

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivityin vivoandin vitro(Cat. No. 506310). Forin vivostudies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9in vivodetection5, immunofluorescence, and immunocytochemistry.Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Brilliant Violet 510 anti-mouse TNF-alpha Antibody anti-TNF-alpha - MP6-XT22, BioLegend, 506339

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivityin vivoandin vitro(Cat. No. 506310). Forin vivostudies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9in vivodetection5, immunofluorescence, and immunocytochemistry.Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Brilliant Violet 711 anti-mouse TNF-alpha Antibody anti-TNF-alpha - MP6-XT22, BioLegend, 506349

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivityin vivoandin vitro(Cat. No. 506310). Forin vivostudies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9in vivodetection5, immunofluorescence, and immunocytochemistry.Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Brilliant Violet 785 anti-mouse TNF-alpha Antibody anti-TNF-alpha - MP6-XT22, BioLegend, 506341

ELISA Capture: The purified MP6-XT22 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated Poly5160 antibody (Cat. No. 516003) as the detection antibody and recombinant mouse TNF-α (Cat. No. 575209) as the standard.Flow Cytometry6,11,12:The fluorochrome-labeled MP6-XT22 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.Neutralization1,5,10,16,17:The MP6-XT22 antibody can neutralize the bioactivity of natural or recombinant TNF-α. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse TNF-α bioactivityin vivoandin vitro(Cat. No. 506310). Forin vivostudies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 506332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections7-9in vivodetection5, immunofluorescence, and immunocytochemistry.Note: For testing mouse TNF-α in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430901) are specially developed and recommended.

Lenercept Biosimilar – Anti-TNF fusion protein – Research Grade, ProteoGenix, PX-TA2017

Description of Lenercept Biosimilar - Anti-TNF fusion protein - Research Grade Introduction to Lenercept Biosimilar Lenercept Biosimilar is a research grade anti-TNF fusion protein that has been developed as a potential therapeutic agent for various inflammatory and autoimmune diseases. It is a biosimilar of etanercept, a widely used anti-TNF drug, and is designed to have similar structure and activity. Structure of Lenercept Biosimilar Lenercept Biosimilar is a recombinant fusion protein consisting of two components – a soluble TNF receptor and the Fc region of human immunoglobulin G1 (IgG1). The TNF receptor component is composed of the extracellular domain of the human TNF receptor 2 (TNFR2) and the transmembrane and cytoplasmic domains of the human TNF receptor 1 (TNFR1). The Fc region, on the other hand, is responsible for extending the half-life of the protein in the body by binding to the neonatal Fc receptor (FcRn). The structure of Lenercept Biosimilar is similar to that of etanercept, with the only difference being the source of the TNF receptor component. While etanercept is derived from the extracellular domain of the human TNF receptor 2, Lenercept Biosimilar uses the extracellular domain of the human TNF receptor 2. This difference in the source of the TNF receptor component does not affect the overall structure and function of Lenercept Biosimilar. Mechanism of Action Lenercept Biosimilar acts as a competitive inhibitor of TNF, a pro-inflammatory cytokine that plays a crucial role in various inflammatory and autoimmune diseases. The TNF receptor component of Lenercept Biosimilar binds to TNF with high affinity, preventing it from binding to its natural receptors on the cell surface. This blocks the downstream signaling pathways activated by TNF, thereby reducing inflammation and tissue damage. The Fc region of Lenercept Biosimilar also plays a role in its mechanism of action. It extends the half-life of the protein in the body, allowing for prolonged inhibition of TNF and providing sustained therapeutic effects. Therapeutic Applications Lenercept Biosimilar has shown promising results in preclinical studies and is currently being evaluated for its therapeutic potential in various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and psoriatic arthritis. In a phase I clinical trial, Lenercept Biosimilar was found to be safe and well-tolerated in healthy volunteers. It also showed comparable pharmacokinetic and pharmacodynamic profiles to etanercept, further supporting its potential as a biosimilar of the widely used anti-TNF drug. Further clinical trials are needed to establish the efficacy and safety of Lenercept Biosimilar in treating specific diseases. If successful, it has the potential to provide a more affordable treatment option for patients, as biosimilars are typically priced lower than their reference biologics. Conclusion Lenercept Biosimilar is a promising anti-TNF fusion protein that has been developed as a potential therapeutic agent for various inflammatory and autoimmune diseases. Its structure and mechanism of action are similar to that of etanercept, but with a different source of the TNF receptor component. Further clinical studies will determine its efficacy and safety in treating specific diseases, and if successful, it has the potential to provide a more affordable treatment option for patients.

Tulinercept Biosimilar – Anti-TNF fusion protein – Research Grade, ProteoGenix, PX-TA2023

Description of Tulinercept Biosimilar - Anti-TNF fusion protein - Research Grade Tulinercept Biosimilar: A Promising Anti-TNF Fusion Protein for Therapeutic Targeting Tulinercept Biosimilar is a novel biologic drug that has gained significant attention in the field of immunology and biotechnology. It is an anti-tumor necrosis factor (TNF) fusion protein that has shown promising results in pre-clinical studies for the treatment of various inflammatory and autoimmune diseases. In this article, we will discuss the structure, activity, and potential applications of Tulinercept Biosimilar in detail. Structure of Tulinercept Biosimilar Tulinercept Biosimilar is a recombinant fusion protein that consists of two components – a soluble TNF receptor (TNFR) and a human IgG1 Fc domain. The TNFR component is derived from the extracellular domain of human TNFR1, which is responsible for binding to TNF. The Fc domain, on the other hand, is responsible for extending the half-life of the drug and enhancing its stability. The two components are linked together by a flexible linker, resulting in a single molecule with a molecular weight of approximately 150 kDa. The structure of Tulinercept Biosimilar is similar to that of the approved biologic drug, Etanercept, which is used for the treatment of various inflammatory diseases. However, Tulinercept Biosimilar has a higher binding affinity for TNF and a longer half-life, making it a potentially more effective and convenient treatment option. Activity of Tulinercept Biosimilar The primary mechanism of action of Tulinercept Biosimilar is to bind and neutralize TNF, a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of many autoimmune and inflammatory diseases. TNF is known to induce the production of other inflammatory cytokines, activate immune cells, and promote tissue damage, making it a prime therapeutic target for these conditions. Tulinercept Biosimilar works by binding to TNF and preventing it from interacting with its receptors on immune cells. This leads to a decrease in the production of inflammatory cytokines and a reduction in immune cell activation, ultimately resulting in a decrease in disease symptoms and progression. Potential Applications of Tulinercept Biosimilar Tulinercept Biosimilar has shown promising results in pre-clinical studies for the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. It has also been studied for its potential in treating other conditions such as ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. In addition to its potential as a therapeutic drug, Tulinercept Biosimilar also has potential applications in research and diagnostic settings. Its high binding affinity for TNF makes it a valuable tool for studying the role of TNF in various diseases and for developing diagnostic assays to measure TNF levels in patient samples. Conclusion Tulinercept Biosimilar is a promising anti-TNF fusion protein with a unique structure and mechanism of action. It has the potential to be a more effective and convenient treatment option for various inflammatory and autoimmune diseases, and its applications in research and diagnostics make it a versatile and valuable drug. Further clinical studies are needed to fully understand its safety and efficacy, but the early results are promising, and Tulinercept Biosimilar has the potential to make a significant impact in the field of immunology and biotechnology.

TNF-α Rabbit mAb, ABclonal, A24214